

Retraction

Retraction: Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma**Mohammad Krayem¹, Ahmad Najem¹, Fabrice Journe^{1,2}, Renato Morandini¹, François Sales¹, Ahmad Awada³ and Ghanem E. Ghanem¹**¹Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium²Service d'Anatomie Humaine et d'Oncologie Expérimentale, Université de Mons, Mons, Belgium³Department of Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium**Published:** June 03, 2024**Copyright:** © 2024 Krayem et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been retracted: Multiple internal duplications of western blot images illustrating the data of different experiments have been discovered throughout Figure 3C. In addition, Figure 3C also contains blots images from Figure 2A in an earlier published paper [1]. Therefore, with the agreement of all authors, the Scientific Integrity office at Oncotarget has decided to retract this paper.

Original article: Oncotarget. 2018; 9:31888–31903. <https://doi.org/10.18632/oncotarget.25879>**REFERENCES**

1. Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Salès F, van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib. Eur J Cancer. 2016; 55:98–110. <https://doi.org/10.1016/j.ejca.2015.12.002>. [PubMed]